InSite Vision: Positive Phase III Trial Results for BromSite Reduces Much of Downside Risk in the Stock (INSV.OB, $0.30)Tuesday, March 19, 2013 · 9:29 am |
|
InSite Vision: Upcoming Topline Results from Clinical Trials Presents a Buying Opportunity (INSV.OB, $0.34)Monday, December 17, 2012 · 11:02 am |
|
Hitting Major Milestones is Driving InSite's Price (INSV.OB, $0.40)Wednesday, September 12, 2012 · 8:15 am |
|
InSite Vision: Initiation of Coverage on Promising Late Stage Ophthalmology Company (INSV, $0.30)Wednesday, June 20, 2012 · 2:46 pm |
|
There are 4 reports on file. |